Nanion

Executive Summary

Nanion Technologies, founded in 2002 and headquartered in Munich, Germany, is a leading provider of high-performance electrophysiology instrumentation for ion channel and transporter research. The company’s product portfolio includes automated patch clamp platforms, membrane biophysics analyzers, and cell analytics tools, which are critical for accelerating drug discovery and development in therapeutic areas such as cardiac safety, CNS disorders, and rare diseases. With a strong emphasis on scientific support and service, Nanion has established itself as a key partner for pharmaceutical and academic labs worldwide, enabling efficient screening of compounds and reducing the time to market for new therapies. As the demand for precision medicine and ion channel-targeted therapies grows, Nanion is well-positioned to expand its market share through continuous innovation and strategic collaborations. The company’s instruments are essential for assessing drug candidates’ safety and efficacy, particularly in cardiac and neurological indications. Looking ahead, Nanion can leverage its expertise to penetrate emerging fields like personalized diagnostics and synthetic biology. While private, the company’s strong intellectual property portfolio and recurring revenue from consumables and service contracts provide a solid foundation for growth. Partnerships with large pharma and entry into new application areas represent key catalysts for expansion.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation high-throughput automated patch clamp system70% success
• Q2 2026Strategic partnership with a major pharmaceutical company for cardiac safety screening60% success
• Q3 2026Expansion into CNS diagnostics with a new membrane biophysics analyzer50% success